Patients who are unable to reliably tolerate and/or receive oral medications
Inability to take oral medications on a continuous basis
Participants must be able to take oral medications
Inability to swallow oral medications
Able to swallow and retain oral medication (note: for patients unable to swallow tablets, an oral suspension preparation is acceptable)
Patients must have the ability to swallow oral medication
Ability to swallow liquids
Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow, retain, and/or absorb the drug are excluded
Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication
Able to swallow and retain oral medication
Ability to swallow oral medications
Subjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel* Active peptic ulcer disease* Malabsorption syndrome
Patients must be able to swallow oral medications
Patients must be able to swallow medication by oral route
Ability to take oral medications
Ability to swallow oral medications
Ability to swallow medication
Ability to swallow oral medications
Patients must be able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparib
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Patients must have the ability to swallow oral dosage forms
Patients must be able to take oral medications (i.e., swallow pills whole); patients must not have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures that could in the opinion of the treating investigator affect absorption, or active peptic ulcer disease; patients with intractable nausea or vomiting are not eligible
Ability to swallow oral medications
Able to take oral medication and has no history of gastric surgery or pathology
Patient is unable to swallow or keep down oral medication
CLINICAL/LABORATORY CRITERIA: Patients must be able to swallow oral medications and must not have a gastro-intestinal disorder with diarrhea as a major symptom or that may alter absorption such as malabsorption syndromes or gastric resection
Ability to swallow and retain oral medication
Patients must have the ability to swallow and retain oral medication
Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain dasatinib tablets are excluded
Subject is able to swallow and retain oral medication and does not have uncontrolled emesis or gastrointestinal disorders likely to interfere with absorption of the study medication
Patients must be able to swallow oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Ability to swallow and retain oral medication
Patients that unable to swallow oral medications are ineligible
